Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Trial in progress: A phase 1b/2a study to evaluate mezigdomide in combination with elranatamab in patients with relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

ZLZihan LinJKJessica KatzLCLuciano J. Costa

Discussion

Loading...

Member takes

Overview

Phase 1b/2a trial evaluates mezigdomide plus elranatamab in relapsed/refractory multiple myeloma, indicating safety and efficacy.

Key Points

  • To assess the safety and preliminary efficacy of mezigdomide and elranatamab in patients with relapsed/refractory multiple myeloma.
  • Multicenter, open-label, phase 1b/2a study with dose escalation and expansion
  • Patients aged ≥18 with relapsed/refractory multiple myeloma
  • Combination treatment of mezigdomide and elranatamab administered over 28-day cycles
  • Assessment of safety focuses on adverse events and dose-limiting toxicities
  • Evaluation of pharmacokinetics and pharmacodynamics during treatment
  • Primary outcome measures include progression-free survival and overall survival rates

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e504https://doi.org/10.1182/blood-2025-8246
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 12025 · 2 citations
  2. 2Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial2023 · 13 citations
  3. 3MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).2024 · 5 citations
  4. 4Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)2025
  5. 5Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study2025